Seite - 66 - in Cancer Nanotheranostics - What Have We Learnd So Far?

MorenoandPêgo AONcancer therapeutics Alkilany, A. M., andMurphy, C. J. (2010). Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J. Nanopart. Res. 12, 2313–2333. doi:10.1007/s11051-010-9911-8 Badros,A.Z.,Goloubeva,O.,Rapoport,A.P.,Ratterree,B.,Gahres,N.,Meisenberg, B., et al. (2005). Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myelomapatients. J.Clin.Oncol.23,4089–4099.doi:10.1200/JCO.2005.14.381 Barchet,W.,Wimmenauer, V., Schlee, M., andHartmann, G. (2008). Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr. Opin. Immunol.20,389–395.doi:10.1016/j.coi.2008.07.007 Bennett, C. F., and Swayze, E. E. (2010). RNA targeting therapeutics: molec- ular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259–293. doi: 10.1146/annurev.pharmtox. 010909.105654 Berger, I., Tereshko, V., Ikeda, H., Marquez, V. E., and Egli, M. (1998). Crystal structures of B-DNAwith incorporated 2′-deoxy-2′-fluoro-arabino-furanosyl thymines: implications of conformational preorganization for duplex stability. NucleicAcidsRes.26,2473–2480.doi:10.1093/nar/26.10.2473 Bestas, B., Moreno, P. M., Blomberg, K. E., Mohammad, D. K., Saleh, A. F., Sutlu,T., et al. (2014). Splice-correctingoligonucleotides restoreBTKfunction inX-linked agammaglobulinemiamodel. J. Clin. Invest. 124, 4067–4081. doi: 10.1172/JCI76175 Brown, D. A., Kang, S. H., Gryaznov, S. M., Dedionisio, L., Heidenreich, O., Sullivan, S., et al. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801–26805. Chauhan,V.P., Stylianopoulos,T.,Boucher,Y., and Jain,R.K. (2011).Deliveryof molecularandnanoscalemedicine to tumors: transportbarriersandstrategies. Annu.Rev.Chem.Biomol.Eng.2,281–298.doi: 10.1146/annurev-chembioeng- 061010-114300 Chauhan,V.P.,Stylianopoulos,T.,Martin,J.D.,Popovic,Z.,Chen,O.,Kamoun,W. S.,etal. (2012).Normalizationoftumourbloodvessels improvesthedeliveryof nanomedicines inasize-dependentmanner.Nat.Nanotechnol.7,383–388.doi: 10.1038/nnano.2012.45 Crooke, S. T., Graham, M. J., Zuckerman, J. E., Brooks, D., Conklin, B. S., Cummins, L. L., et al. (1996). Pharmacokinetic properties of several novel oligonucleotideanalogs inmice. J.Pharmacol.Exp.Ther.277,923–937. Delong, R. K., Nolting, A., Fisher,M., Chen, Q.,Wickstrom, E., Kligshteyn,M., et al. (1997). Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, andmethylphospho- nateoligonucleotides innudemice.AntisenseNucleicAcidDrugDev.7, 71–77. doi:10.1089/oli.1.1997.7.71 Devi, G. R., Beer, T.M., Corless, C. L., Arora, V.,Weller,D. L., and Iversen, P. L. (2005).Invivobioavailabilityandpharmacokineticsofac-MYCantisensephos- phorodiamidatemorpholinooligomer,AVI-4126, insolid tumors.Clin.Cancer Res.11,3930–3938.doi:10.1158/1078-0432.CCR-04-2091 Ding, Y., Jiang, Z., Saha, K., Kim, C. S., Kim, S. T., Landis, R. F., et al. (2014). Gold nanoparticles for nucleic acid delivery.Mol. Ther. 22, 1075–1083. doi: 10.1038/mt.2014.30 Dirin,M., andWinkler, J. (2013). Influence of diverse chemicalmodifications on theADMEcharacteristics and toxicology of antisense oligonucleotides.Expert Opin.Biol.Ther.13,875–888.doi:10.1517/14712598.2013.774366 Disterer, P., Kryczka, A., Liu, Y., Badi, Y. E.,Wong, J. J.,Owen, J. S., et al. (2014). Developmentoftherapeuticsplice-switchingoligonucleotides.Hum.GeneTher. 25,587–598.doi:10.1089/hum.2013.234 Eckstein, F. (1967). A dinucleoside phosphorothioate. Tetrahedron Lett. 8, 1157–1160.doi:10.1016/S0040-4039(00)90656-7 Fang, J., Nakamura, H., and Maeda, H. (2011). The EPR effect: unique fea- tures of tumor blood vessels for drug delivery, factors involved, and limita- tions and augmentation of the effect.Adv. DrugDeliv. Rev. 63, 136–151. doi: 10.1016/j.addr.2010.04.009 Geary,R. S. (2009).Antisenseoligonucleotidepharmacokinetics andmetabolism. ExpertOpin.DrugMetab.Toxicol.5,381–391.doi:10.1517/17425250902877680 Gekeler, V., Gimmnich, P., Hofmann, H. P., Grebe, C., Rommele, M., Leja, A., et al. (2006). G3139 and other CpG-containing immunostimulatory phos- phorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 16, 83–93. doi: 10.1089/oli.2006.16.83 Gokhale, P. C., Zhang, C., Newsome, J. T., Pei, J., Ahmad, I., Rahman, A., et al. (2002). Pharmacokinetics, toxicity, and efficacy of ends-modified raf anti- senseoligodeoxyribonucleotideencapsulatedinanovelcationic liposome.Clin. CancerRes.8,3611–3621. Gomes, C. P., Ferreira Lopes, C. D., DuarteMoreno, P. M., Varela-Moreira, A., Alonso,M. J., and Pêgo, A. P. (2014). Translating chitosan to clinical delivery ofnucleicacid-baseddrugs.MRSBull.39,60–70.doi:10.1557/mrs.2013.314 Graham,M. J., Crooke, S. T.,Monteith, D. K., Cooper, S. R., Lemonidis, K.M., Stecker, K. K., et al. (1998). In vivo distribution andmetabolism of a phos- phorothioateoligonucleotidewithin rat liver after intravenous administration. J.Pharmacol.Exp.Ther.286,447–458. Hammond,S.M.,andWood,M.J. (2011).Genetic therapies forRNAmis-splicing diseases.TrendsGenet.27,196–205.doi:10.1016/j.tig.2011.02.004 Henry, S. P., Templin, M. V., Gillett, N., Rojko, J., and Levin, A. A. (1999). Correlationof toxicity andpharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.Toxicol. Pathol. 27, 95–100. doi: 10.1177/019262339902700117 Henry, S., Stecker, K., Brooks, D., Monteith, D., Conklin, B., and Bennett, C. F. (2000). Chemically modified oligonucleotides exhibit decreased immune stimulation inmice. J.Pharmacol.Exp.Ther.292,468–479. Hong,D. S., Kurzrock, R.,Oh, Y.,Wheler, J., Naing, A., Brail, L., et al. (2011). A phase1doseescalation,pharmacokinetic, andpharmacodynamicevaluationof eIF-4E antisense oligonucleotide LY2275796 inpatientswith advanced cancer. Clin.CancerRes.17,6582–6591.doi:10.1158/1078-0432.CCR-11-0430 Hovingh, K., Besseling, J., and Kastelein, J. (2013). Efficacy and safety of mipomersen sodium (Kynamro). Expert Opin. Drug Saf. 12, 569–579. doi: 10.1517/14740338.2013.793670 Iversen,P. L.,Copple,B. L., andTewary,H.K. (1995). Pharmacology and toxicol- ogyofphosphorothioateoligonucleotides in themouse, rat,monkeyandman. Toxicol.Lett.82–83,425–430.doi:10.1016/0378-4274(95)03572-9 Jaaskelainen, I., Peltola, S.,Honkakoski,P.,Monkkonen, J., andUrtti,A. (2000).A lipid carrierwith amembrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonu- cleotides.Eur. J.Pharm.Sci.10,187–193.doi:10.1016/S0928-0987(00)00068-3 Jain,R.K.(2012).Deliveryofmolecularandcellularmedicinetosolidtumors.Adv. DrugDeliv.Rev.64,353–365.doi:10.1016/j.addr.2012.09.011 Jang,S.H.,Wientjes,M.G.,Lu,D.,andAu,J.L.(2003).Drugdeliveryandtransport tosolid tumors.Pharm.Res.20,1337–1350.doi:10.1023/A:1025785505977 Juliano,R.,Bauman, J.,Kang,H., andMing,X. (2009).Biologicalbarriers to ther- apywith antisense and siRNAoligonucleotides.Mol. Pharm. 6, 686–695. doi: 10.1021/mp900093r Juliano, R. L., Ming, X., and Nakagawa, O. (2012). The chemistry and biol- ogy of oligonucleotide conjugates. Acc. Chem. Res. 45, 1067–1076. doi: 10.1021/ar2002123 Kawai, G., Yamamoto, Y., Kamimura, T., Masegi, T., Sekine, M., Hata, T., et al. (1992). Conformational rigidity of specific pyrimidine residues in tRNA arises from posttranscriptional modifications that enhance steric interaction between the base and the 2′-hydroxyl group.Biochemistry 31, 1040–1046. doi: 10.1021/bi00119a012 Kibler-Herzog, L., Zon, G., Uznanski, B., Whittier, G., and Wilson, W. D. (1991). Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers. Nucleic Acids Res. 19, 2979–2986. doi: 10.1093/nar/19.11.2979 Koshkin,A.A.,Singh,S.K.,Nielsen,P.,Rajwanshi,V.K.,Kumar,R.,Meldgaard,M., et al. (1998). LNA (LockedNucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleosidemonomers, oligomerisation, and unprecedented nucleic acid recognition.Tetrahedron 54, 3607–3630.doi:10.1016/S0040-4020(98)00094-5 Krieg, A.M., Guga, P., and Stec,W. (2003). P-chirality-dependent immune acti- vation by phosphorothioate CpG oligodeoxynucleotides.Oligonucleotides 13, 491–499.doi:10.1089/154545703322860807 Krieg, A. M., and Stein, C. A. (1995). Phosphorothioate oligodeoxynucleotides: antisenseoranti-protein?AntisenseRes.Dev.5,241. Manoharan,M.(1999).2′-carbohydratemodificationsinantisenseoligonucleotide therapy: importanceofconformation,configurationandconjugation.Biochim. Biophys.Acta1489,117–130.doi:10.1016/S0167-4781(99)00138-4 Meidan, V.M., Glezer, J., Amariglio, N., Cohen, J. S., and Barenholz, Y. (2001). Oligonucleotide lipoplexes: the influence of oligonucleotide composition on Frontiers inChemistry | ChemicalEngineering October2014 |Volume2 |Article87 | 66